Here are four insights:
1. The researchers were interested in identifying differences in protection with the 2014 to 2015 seasonal flu vaccine against the various genetic groups of the H3N2 viruses.
2. The study revealed the flu vaccine offered moderate protection (44 percent) against one genetic group of H3N2 viruses, antigenically similar to the vaccine’s H3N2 component.
3. The flu vaccine offered no protection against the “most commonly circulating group of H3N2 viruses that was substantially different antigenically from the flu vaccine’s H3N2 component,” however.
4. The researchers concluded their study reveals the benefits of utilizing laboratory-based methods to pinpoint genetic properties of flu viruses for flu vaccine selection.
More articles on quality & infection control:
5 key notes on workplace violence in healthcare
Premier ranks 1st in healthcare management consulting report: 5 highlights
National Patient Safety Foundation adds 5 members to patient safety program: 4 highlights
